Stockhead – PharmAust’s MPL could offer MND/ALS patients up to 56.5 months additional life expectancy MediaBy Nickholas Bahr28/02/2024
Small Caps – PharmAust’s monepantel study shows 58% slowdown in MND progression MediaBy Nickholas Bahr28/02/2024
